Lung cancer biomarker testing: perspective from Europe
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F20%3A10416250" target="_blank" >RIV/00216208:11150/20:10416250 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/20:10416250
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=vbdS9Wl_5F" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=vbdS9Wl_5F</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21037/tlcr.2020.04.07" target="_blank" >10.21037/tlcr.2020.04.07</a>
Alternative languages
Result language
angličtina
Original language name
Lung cancer biomarker testing: perspective from Europe
Original language description
A questionnaire on biomarker testing previously used in central European countries was extended and distributed in Western and Central European countries to the pathologists participating at the Pulmonary Pathology Society meeting 26-28 June 2019 in Dubrovnik, Croatia. Each country was represented by one responder. For recent biomarkers the availability and reimbursement of diagnoses of molecular alterations in non-small cell lung carcinoma varies widely between different, also western European, countries. Reimbursement of such assessments varies widely between unavailability and payments by the health care system or even pharmaceutical companies. The support for testing from alternative sources, such as the pharmaceutical industry, is no doubt partly compensating for the lack of public health system support, but it is not a viable or long-term solution. Ideally, a structured access to testing and reimbursement should be the aim in order to provide patients with appropriate therapeutic options. As biomarker enabled therapies deliver a 50% better probability of outcome success, improved and unbiased reimbursement remains a major challenge for the future.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Translational Lung Cancer Research [online]
ISSN
2218-6751
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
3
Country of publishing house
HK - HONG KONG
Number of pages
18
Pages from-to
887-904
UT code for WoS article
000547884300052
EID of the result in the Scopus database
2-s2.0-85090191489